A Research Study for Adult Women with Recurrent High-grade serous, Endometrioid, or Clear Cell Ovarian, Fallopian Tube or Primary Peritoneal Cancer

IRB/UVA Tracking #
19532
Principal Investigator
Linda R Duska
Contact
Sheena Clift
Contact Phone
434.924.2745
Official Trial Title
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors
Study Description

The UVA Cancer Center seeks women ages 18 and over who have endometrial cancer, or a type of cancer with a specific defect in the tumor DNA, or recurrent high-grade serous, endometrioid, or clear cell ovarian, fallopian tube, or primary peritoneal cancer for a clinical trial.

The purpose of the Phase 2b portion of this study is to evaluate the ability of the study drug, Dostarlimab, to reduce the size of your cancer.

The overall trial does not have a set duration, study treatment will continue for as long are your study doctor thinks the medicine is helping you or another reason for discontinuation has been presented. Patients will be followed for safety for 30 days following discontinuation of study drug. If you decide to withdraw from the study treatment you will be requested to visit your study site within 30 days of your last dose to have your End of Treatment visit performed. You will not be able to request the removal of your information from the study data after it has been collected.

If eligible and you choose to participate, research-specific tests and the study drug, Dostarlimab, will be provided at no cost to you. You or your insurance company are responsible for the standard-of-care exams, blood tests, scans, procedures, clinical visits, etc.

Additional information can be found here: NCT02715284

You will be reimbursed $81 per visit for your travel expenses.

Compensation

No Compensation